Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $148M | $228M | $78.4M | $75.5M | $116M | $332M | $403M |
| Revenue growth | — | — | — | — | 53.4% | -65.5% | -3.8% | 54.1% | 185.7% | 21.3% |
| Operating income | -$76.2M | -$169M | -$205M | -$93.1M | -$121M | -$227M | -$180M | -$156M | $54.4M | $60.3M |
| Operating margin | — | — | — | -62.8% | -53.3% | -289.0% | -237.8% | -133.7% | 16.4% | 15.0% |
| Net income | -$75.0M | -$167M | -$202M | -$97.2M | -$144M | -$269M | -$234M | -$209M | -$51.7M | -$22.7M |
| Net margin | — | — | — | -65.5% | -63.1% | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
| EPS (diluted) | -$3.33 | -$6.98 | -$7.54 | -$3.59 | -$5.23 | -$9.31 | -$3.52 | -$2.03 | -$0.28 | -$0.11 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$47.7M | -$131M | -$149M | -$70.3M | -$85.2M | -$264M | -$175M | -$135M | -$23.7M | -$13.1M |
| Capital expenditures | $94.0K | $19.0K | $151K | $953K | $869K | $0.00 | $0.00 | $0.00 | $317K | $0.00 |
| Free cash flow | -$47.8M | -$131M | -$149M | -$71.3M | -$86.0M | -$264M | -$175M | -$135M | -$24.0M | -$13.1M |
| Share buybacks | — | — | $0.00 | $0.00 | $55.0M | $0.00 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $38.2M | $34.5M | $37.0M | $166M | $305M | $209M | $125M | $82.2M | $145M | $168M |
| Total assets | $245M | $278M | $143M | $214M | $353M | $382M | $248M | $206M | $344M | $466M |
| Total liabilities | $16.6M | $33.1M | $64.3M | $194M | $449M | $579M | $572M | $661M | $733M | $768M |
| Long-term debt | $1.02M | — | — | — | — | — | — | — | — | — |
| Shareholders' equity | $229M | $245M | $79.1M | $19.9M | -$96.1M | -$197M | -$324M | -$455M | -$389M | -$302M |
| Retained earnings | -$229M | -$396M | -$598M | -$695M | -$839M | -$1.11B | -$1.34B | -$1.55B | -$1.60B | -$1.62B |
| Shares (wtd avg diluted) | 22.6M | 26.3M | 26.8M | 27.1M | 27.5M | 28.9M | 66.4M | 103M | 187M | 208M |
Every figure is extracted from Esperion Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.